

NEW OPTIONS IN HCV THERAPY:

UPDATE
FROM
AASLD
2014

Speaker:
Mark Sulkowski, MD

Thursday, January 29, 2015
6:15 – 8:45 PM

Capital Grille
444 Brickell Avenue
Miami, FL 33131

This activity is jointly provided by:



Target Audience

This activity is designed for gastroenterologists, infectious disease specialists, internists, nurse practitioners, physician assistants, and other health care providers involved in the care and management of patients with hepatitis C infection.

Learning Objectives

As a result of this educational activity, participants will be able to:

1. Delineate which subgroups of patients with HCV infection are likely to benefit from HCV therapy that includes a direct antiviral
2. Implement cost-effective procedures to stage liver disease in patients with HCV infection, before and during antiviral treatment
3. Select the best therapy for HCV patients with specific disease characteristics using evidence-based data
4. List common adverse events associated with HCV therapy that includes a direct antiviral
5. Discuss which HCV therapies may be appropriate for pre- and post-liver transplant patients

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Wisconsin School of Medicine and Public Health and the Liver Institute and Foundation for Education and Research (L.I.F.E.R.). The University of Wisconsin School of Medicine and Public Health is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Wisconsin School of Medicine and Public Health designates this live activity for a maximum of **2.0 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support

This CME-certified activity is supported through educational grants from AbbVie and Janssen.

Policy on Disclosure

It is the policy of the University of Wisconsin School of Medicine and Public Health that anyone with a CME planning role for this activity (persons who may influence content) disclose all relevant financial relationships with commercial interests* in order to allow CME staff to identify and resolve any potential conflicts of interest. Detailed disclosures will be made available in the meeting materials.

*The ACCME defines a commercial interest as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

Agenda

- 6:15 – 6:30 PM Registration and Pre-Assessment
- 6:30 – 8:30 PM Dinner and Case Presentations
- 6:30 – 6:50 PM Case 1
- 6:50 – 7:00 PM Discussion
- 7:00 – 7:20 PM Case 2
- 7:20 – 7:30 PM Discussion
- 7:30 – 7:50 PM Case 3
- 7:50 – 8:00 PM Discussion
- 8:00 – 8:20 PM Case 4
- 8:20 – 8:30 PM Discussion
- 8:30 – 8:45 PM Post-Assessment



Meeting Date and Location:

Thursday, January 29, 2015

Capital Grille

444 Brickell Avenue
Miami, FL 33131

Featuring the Following Faculty Presenter:

Mark Sulkowski, MD

Professor of Medicine
Medical Director, Viral Hepatitis Center
Divisions of Infectious Diseases and
Gastroenterology/Hepatology
Department of Medicine
Johns Hopkins University School of Medicine

The following topics will be covered during the case presentations:

1. Current efficacy and safety data for HCV directly acting antivirals in clinical use and due to enter the clinic
2. Integration of simeprevir- and sofosbuvir-based regimens into clinical practice for treating HCV – data from TARGET and TRIO, real-life studies from AASLD
3. Delineation of which regimens are best for patients on the basis of specific HCV disease characteristics
4. Identification of chronic HCV patients that may benefit from delaying treatment - prioritization of care according to AASLD guidelines
5. Integration of new diagnostic technologies, such as fibrosis markers and genetic tests for treatment response, into the cost-effective management of patients with chronic HCV
6. Best practices for management of special populations, including patients for whom prior treatment has failed; those with cirrhosis; and pre- and postliver transplant patients

Elements of Competence

This CME activity has been designed to change learner competence and focuses on the American Board of Medical Specialties (ABMS) areas of medical knowledge and patient care and procedural skills, two of the six competencies set forth by the ABMS.

Statement of Need

The needs assessment reflects—

1. U.S. FDA approval of simeprevir-based therapy for HCV genotype 1 patients and expected approval of sofosbuvir-based therapy for HCV genotypes 1–4
2. Increases in patients identified as having chronic HCV because of expanded screening recommendations from the CDC (Smith BD, et al. MMWR. 2012;61[RR04]:1–18)
3. Limited HCV treatment options for pre- and post-liver transplant patients
4. A lack of guidelines for treating HCV with the novel therapies
5. Previous activity evaluations from the Liver Institute and Foundation for Education and Research (L.I.F.E.R) meetings held in 2004–2013
6. Discussions with community-based gastroenterologists and physician extenders

Title IX and ADA Statement

The University of Wisconsin provides equal opportunities in employment and programming, including Title IX requirements. The University of Wisconsin School of Medicine and Public Health fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in the educational activity is in need of accommodations, please notify **Leslie Jacus** by calling **262-352-5980** in order to receive service.

Registration Information

(Please print legibly and use a pen)

Thursday, January 29, 2015

6:15 – 8:45 PM

Capital Grille
444 Brickell Avenue
Miami, FL 33131

You can register:

By faxing this form to: 262-364-3664

NO REGISTRATION FEE

or

Online: www.liver-institute.org

Email: lesliejacus@enabl-ed.org

Phone: 262-352-5980

First, Middle, and Last Name _____ Degree(s) _____

Organization _____

Street Address _____

City _____ State _____ Zip Code _____

Phone _____ Fax _____

Email _____

Special Accommodations/Comments _____

FAX TO: 262-364-3664